← Leaderboards
Geraint Davies
Harvard Medical School
$4,246,623
Attributed
$8,493,245
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2011–13$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
Funding mix
By agency
NIH$8,493,245 · 1
By mechanism
U01$8,493,245 · 1
Top collaborators
- Carole D Mitnick3 shared
Most similar at Harvard Medical School
Same institution · by research overlap
- Jeffrey R. Starke$2,653,443
- Aedin C Culhane$2,653,443
- Ann Chesney Miller$2,653,443
- Jerome Timothy Galea$2,653,443
- John J Mekalanos$34,471,043
Others in their field
Top investigators on “Animals”
- David Heimbrook · Leidos Biomedical Research, Inc.$534,904,829
- Richard Webby · St. Jude Children'S Research Hospital$259,408,394
- Eric S Lander · Whitehead Institute For Biomedical Res$209,574,154
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Richard K. Wilson · Washington University$130,501,539
- Mark S Klempner · Tufts Medical Center$129,182,794
Research focus
AnimalsAntimicrobialAntitubercular AgentsAreaBacillus (Bacterium)BactericideBaseBlindedBrazilCompanionsConsentDetectionDiagnosticDoseDrug KineticsDrug ResistanceEvaluationExtreme Drug Resistant TuberculosisFailure (Biologic Function)Frequencies (Time Pattern)Group InterventionHealth PersonnelHealth Services AccessibilityAdverse Event
Grant awards (3)
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB$2,289,159
U01 · FY2013 · AI
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB$3,094,141
U01 · FY2012 · AI
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB$3,109,945
U01 · FY2011 · AI